COGT: SEC Form 10-Q filed by Cogent Biosciences Inc.
Q3 2026 10-Q: nine-month net loss $305.2M, accumulated deficit $1,493.6M, 173.99M shares outstanding, cash said sufficient for operations.
What this filing says
Cogent Biosciences reported its quarterly results for the period ended September 30, 2026. The filing shows a net loss of $305.2 million for the nine months and an accumulated deficit of $1,493.6 million, and the company expects to keep incurring operating losses. Management states that current cash, cash equivalents and marketable securities should be enough to fund operations and capital spending, and the company has an at-the-market share sales program in place with Guggenheim Securities.
Key figures
- Nine-month net loss
- $305.2 million
- Accumulated deficit
- $1,493.6 million
- Shares outstanding (Nov 3, 2026)
- 173,994,452 shares
- July 2025 offering net proceeds
- $215.8 million
- July 2025 offering price
- $9.00 per share
Positive for shareholders
- Management expects existing cash, cash equivalents and marketable securities to cover operating and capital expenditure needs.
Negative for shareholders
- The company has incurred recurring losses since inception and expects operating losses to continue.
- The accumulated deficit stands at $1,493.6 million.
- An at-the-market program allows the company to sell additional common stock at market prices, which could dilute existing holders.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- At-the-market offering:
- A way for a company to sell new shares gradually into the open market through a sales agent, at prevailing prices, rather than in one large deal.
- Accumulated deficit:
- The total of all past net losses a company has recorded since it was founded, reduced by any profits.
- Series A Preferred Stock:
- A class of preferred shares that ranks ahead of common stock for certain payments and can often be converted into common shares.
FAQ
How much did Cogent Biosciences lose in the first nine months of 2026?
The filing reports a net loss of $305.2 million for the nine months ended September 30, 2026.
Does Cogent Biosciences expect to have enough cash to keep operating?
The company states that its cash, cash equivalents and marketable securities are expected to be sufficient to fund operating expenses and capital expenditure requirements.
Historical context for COGT
Across the 27 sessions after earlier COGT headlines, the stock closed higher 17 times and lower 10 times, with a median move of 2.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
Keep researching COGT
- COGT financial statementsRevenue, profit, cash flow and balance sheet from Cogent Biosciences Inc.'s SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- COGT insider tradesEvery buy and sale reported by Cogent Biosciences Inc. officers, directors and large holders.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Follow COGT and get a push notification the moment its next story breaks.